Lilly Partners with Dako to Develop Companion Dx for Unnamed Cancer Rx
January 07, 2013
Lilly Partners with Dako to Develop Companion Dx for Unnamed Cancer Rx
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- MDx/CDx Focus: EMA Okays Perjeta; Published Study on Prolaris; HER2 Tests for Kadcyla Clear FDA
March 6, 2013 / Pharmacogenomics Reporter - MDx/CDx Focus: Dako, Pfizer Collaborate on Companion Tests; New Study on MDxHealth's ConfirmMDx
February 13, 2013 / Pharmacogenomics Reporter - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter - 'Omics, MDx M&A Activity Down Slightly in 2012; Rebound May Not Come Until 2014
December 27, 2012 / GenomeWeb Daily News - BRIMS-Led Study Suggests Clinical Viability of SRM-MS, Vendors' Role in Clinical Proteomics Process
June 8, 2012 / ProteoMonitor